138 related articles for article (PubMed ID: 12911586)
21. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
22. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
23. Lack of both α2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production.
Okada K; Ueshima S; Kawao N; Yano M; Tamura Y; Tanaka M; Sakamoto A; Hatano M; Arima M; Miyata S; Nagai N; Tokuhisa T; Matsuo O
Life Sci; 2013 Jul; 93(2-3):89-95. PubMed ID: 23770230
[TBL] [Abstract][Full Text] [Related]
24. Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.
Reed GL; Houng AK; Wang D
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2586-93. PubMed ID: 25256235
[TBL] [Abstract][Full Text] [Related]
25. The kidney is a major site of alpha(2)-antiplasmin production.
Menoud PA; Sappino N; Boudal-Khoshbeen M; Vassalli JD; Sappino AP
J Clin Invest; 1996 Jun; 97(11):2478-84. PubMed ID: 8647939
[TBL] [Abstract][Full Text] [Related]
26. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.
Suelves M; López-Alemany R; Lluís F; Aniorte G; Serrano E; Parra M; Carmeliet P; Muñoz-Cánoves P
Blood; 2002 Apr; 99(8):2835-44. PubMed ID: 11929773
[TBL] [Abstract][Full Text] [Related]
27. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
[TBL] [Abstract][Full Text] [Related]
28. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions.
Tashima Y; Banno F; Kita T; Matsuda Y; Yanamoto H; Miyata T
PLoS One; 2017; 12(7):e0180981. PubMed ID: 28686706
[TBL] [Abstract][Full Text] [Related]
30. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
31. Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Hayashido Y; Hamana T; Ishida Y; Shintani T; Koizumi K; Okamoto T
Oncol Rep; 2007 Feb; 17(2):417-23. PubMed ID: 17203182
[TBL] [Abstract][Full Text] [Related]
32. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
Butte AN; Houng AK; Jang IK; Reed GL
Circulation; 1997 Apr; 95(7):1886-91. PubMed ID: 9107177
[TBL] [Abstract][Full Text] [Related]
33. An animal model for venous thrombosis and spontaneous pulmonary embolism.
Frisbie JH
Spinal Cord; 2005 Nov; 43(11):635-9. PubMed ID: 15951743
[TBL] [Abstract][Full Text] [Related]
34. Gene targeting in hemostasis. Alpha2-antiplasmin.
Lijnen HR
Front Biosci; 2001 Feb; 6():D239-47. PubMed ID: 11171550
[TBL] [Abstract][Full Text] [Related]
35. Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity.
Malayaman SN; Cohen JB; Machovec KA; Bernhardt BE; Arkebauer MR; Nielsen VG
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):345-8. PubMed ID: 21330914
[TBL] [Abstract][Full Text] [Related]
36. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
[TBL] [Abstract][Full Text] [Related]
37. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.
Kawasaki T; Dewerchin M; Lijnen HR; Vermylen J; Hoylaerts MF
Blood; 2000 Jul; 96(1):153-60. PubMed ID: 10891445
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Shaya SA; Saldanha LJ; Vaezzadeh N; Zhou J; Ni R; Gross PL
J Thromb Haemost; 2016 Jan; 14(1):143-52. PubMed ID: 26514101
[TBL] [Abstract][Full Text] [Related]
39. A systematic review on internal jugular vein thrombosis and pulmonary embolism.
Drakos P; Ford BC; Labropoulos N
J Vasc Surg Venous Lymphat Disord; 2020 Jul; 8(4):662-666. PubMed ID: 32321692
[TBL] [Abstract][Full Text] [Related]
40. 28-day thawed plasma maintains α
Stettler GR; Moore EE; Huebner BR; Nunns GR; Moore HB; Coleman JR; Kelher M; Banerjee A; Silliman CC
Vox Sang; 2021 Feb; 116(2):181-189. PubMed ID: 32894784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
